Article

Response to COVID-19 booster vaccinations in seronegative people with MS

2022-03-13

Abstract excerpt

<h4>Background</h4> Uncertainties remain about the benefit of a 3rd COVID-19 vaccine for people with attenuated response to earlier vaccines. This is of particular relevance for people with multiple sclerosis (pwMS) treated with anti-CD20 therapies and fingolimod, who have substantially reduced antibody responses to initial vaccine course. <h4>Methods</h4> PwMS taking part in a seroprevalence study without a detec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dc508a9d-56ce-58d0-8b09-0c5c6600e065
DOI: 10.1101/2022.03.12.22272083

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Response to COVID-19 booster vaccinations in seronegative people with MSDOI 10.1101/2022.03.12.22272083Read

Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity Read

Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patientsSemantic proximity Read

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity Read

Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity Read

SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumabSemantic proximity Read

Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity Read

T cell responses to SARS-CoV-2 vaccination in people with multiple sclerosis differ between disease-modifying therapiesSemantic proximity Read

COVID-19 prevention with alternate vaccine boosting frequencies for multiple-sclerosis patients undergoing therapy with beta-interferon, dimethyl fumarate, natalizumab, or teriflunomideSemantic proximity Read

Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple SclerosisSemantic proximity Read

Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapySemantic proximity Read

Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 VaccinationSemantic proximity Read

Antibody response against SARS-CoV-2 spike protein in people with HIV after COVID-19 vaccinationSemantic proximity Read